How far have we come in raw material supply management, and what still needs accomplished to ensure the delivery of safe and effective drugs?
Identifying the optimal formulation and dose form which shows an increase more than 20 times in the oral bioavailability of Salmon Calcitonin.
In today’s changing industry, it is critical we consider several factors about cell culture bioprocessing and the impact they will have on the future of patient treatment.
When it comes to some aspects of healthcare, like medical devices or drug therapies, personalization has long been out of reach. Today, that is changing. This video highlights how the life sciences industry can now see unique patient populations at a deeper, more meaningful level. This means it can develop targeted therapies to help those populations.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Biologic manufacturing subjects the formulation to different stresses and conditions that may compromise quality and stability. Recently, the requirement for the development of subcutaneous formulations for high dose drugs, such as monoclonal antibodies, at high protein concentrations has created additional challenges, including degradation. Read about the options provided by wearable technology offers new alternatives that were not previously possible due to historically binding parameters for formulators.
Leveraging external experts for analytical input provides a cost-effective route to the latest instrumentation, robust and precise measurement, and reliable data interpretation.
This study presents how strategic enhancements to the sparge and agitation systems of Thermo Scientific HyPerforma S.U.B.s have revealed the potential for a three- to four-fold improvement in mixing and mass transfer performance compared to legacy S.U.B. designs.
IASO supports stakeholders who are responsible for bringing innovation to market in the form of combination products for oncology.
Nanoparticle size analyzer with zeta potential measurements.
The new Zetasizer Ultra is our most advanced system for the measurement of particle and molecular size, particle charge and particle concentration, and represents the most intelligent and flexible instrument in the Zetasizer range.
The CP100WX is a general-purpose Ultracentrifuge with outstanding performance up to 100,000 rpm assisting in a wide range of separation protocols in involving proteins, DNA, RNA, metal nano-colloids, and more. Reliable and efficient the Hitachi CP100WX features a Rotor Life Management (RLM) system to automatically maintain rotor logging history maximizing rotor life.
The CFS 1500™ is a capsule filling and sealing machine and is a part of the Lonza Engine™ equipment portfolio, which was created to support bioavailability enhancement, encapsulation and early-phase clinical development technologies. To learn more about its capabilities and specifications, download the brochure.
Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.
The user-friendly Prism™ Mini is a reliable, compact, and economical personal microcentrifuge ideal for quick spins that can be used for a wide range of molecular biology protocols. Prism™ Mini works out of the box with a maintenance-free drive system and advanced design providing quiet operation and proper ventilation protecting temperature-sensitive samples. Prism™ Mini includes two (2) quick release interchangeable rotors with a max speed up to 6000 RPM.
